![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||
MECHANISTIC PATHWAYS AND BIOLOGICAL ROLES FOR RECEPTOR-INDEPENDENT ACTIVATORS OF G-PROTEIN SIGNALING Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, 1901 Perdido Street, New Orleans, LA 70112 *Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 711, Rochester, NY 14642-8711 ** Corresponding Author, Stephen M. Lanier, Ph.D., Department of Pharmacology, Medical University of South Carolina, Colcock Hall, 2nd Floor, PO Box 250002, 179 Ashley Avenue, Charleston, SC 29425, 843-792-0442, E-mail: laniersm/at/musc.edu The publisher's final edited version of this article is available at Pharmacol Ther. See other articles in PMC that cite the published article.Abstract Signal processing via heterotrimeric G-proteins in response to cell surface receptors is a central and much investigated aspect of how cells integrate cellular stimuli to produce coordinated biological responses. The system is a target of numerous therapeutic agents, plays an important role in adaptive processes of organs, and aberrant processing of signals through these transducing systems is a component of various disease states. In addition to GPCR-mediated activation of G-protein signaling, nature has evolved creative ways to manipulate and utilize the Gαβγ heterotrimer or Gα and Gαβγ subunits independent of the cell surface receptor stimuli. In such situations, the G-protein subunits (Gα and Gαβγ) may actually be complexed with alternative binding partners independent of the typical heterotrimeric Gαβγ. Such regulatory accessory proteins include the family of RGS proteins that accelerate the GTPase activity of Gα and various entities that influence nucleotide binding properties and/or subunit interaction. The latter group of proteins includes receptor independent activators of G-protein signaling or AGS proteins that play surprising roles in signal processing. This review provides an overview of our current knowledge regarding AGS proteins. AGS proteins are indicative of a growing number of accessory proteins that influence signal propagation, facilitate cross talk between various types of signaling pathways and provide a platform for diverse functions of both the heterotrimeric Gαβγ and the individual Gα and Gαβγ subunits. Keywords: G-proteins, Activators of G-protein signaling, nucleotide exchange, signal transduction, G-protein signaling modulators 1. INTRODUCTION Signal processing via heterotrimeric G-protein proteins generally involves an initial input sensed by a cell surface GPCR leading to conformational changes in receptor subdomains then transfer this signal to a G-protein, promoting exchange of GTP for GDP and subunit dissociation or rearrangement allowing Gα and Gαβγ to regulate a number of downstream signaling molecules. Multiple discoveries over the last several years have forced us to broaden our perspective on the role of G-proteins as “signaling switches” recognizing 1) that these entities are regulating intracellular events independent of their role as transducers for GPCRs, 2) the Gα and Gαβγ subunits may function independently of each other and 3) the existence of accessory proteins that provide unexpected modes of signal input in this context. The discovery of alternative modes of regulation of G-proteins and unexpected functional roles for these proteins resulted from a confluence of several independent lines of investigation. A biochemical approach built upon data suggesting cell-specific differences in signal transfer from R to G, the partial purification of a putative non-receptor G-protein activator from extracts of NG108-15 cells and the identification of other non-receptor proteins that could influence the activation state of G-proteins (see Cismowski and Lanier, 2005). An extension of this line of investigation led to the development of a functional yeast-based screen for mammalian entities that activated G-protein signaling in the absence of a receptor (Cismowski et al., 1999; Takesono et al., 1999). In parallel with these studies was the initiative of several labs to search for Gα and Gαβγ binding partners in yeast two hybrid screens, (see Table III in Sato et al., 2006a) and the realization that G-protein subunits were associated with intracellular organelles (Stow et al., 1991; Wilson et al., 1994). Interspersed with these biochemical approaches was the realization that there were changes in signal processing through G-protein signaling systems that occurred independent of any obvious changes in receptor number or G-protein expression levels suggesting additional undefined regulatory mechanisms.
Another line of investigation evolved out of the study of asymmetric cell division in D. melanogaster neuroblasts and sensory organ precursor cells in parallel with the C. elegans embryo. Gotta and Arhinger reported that Gβγ regulated the orientation of the mitotic spindle in C. elegans in the one-cell embryo (Gotta and Ahringer, 2001). In addition, Gα and a protein containing a G-protein regulatory (GPR) motif (a signature feature of Group II AGS proteins discussed in detail later in this review) interacting with Gα, were identified as regulators of asymmetric cell division in a large scale RNAi-based functional screen (Kamath et al., 2003). Parallel studies in D. melanogaster also led to the identification of key players involved in this biological process (Betschinger and Knoblich, 2004). One of these key players was Pins, which contains four GPR motifs and is an ortholog of the Group II AGS proteins AGS3 and LGN discussed later in this review. Pins and its binding partner Insc influence the positioning of cell fate determinants to generate asymmetry and are important for the stability and targeting of protein complexes that transmit polarity information at the apical cortex of the neuroblast to orient the mitotic spindle. Notably, Pins was identified as a binding partner of Gα (Bellaiche et al., 2001; Parmentier et al., 2000; Schaefer et al., 2001; Schaefer et al., 2000; Yu et al., 2000). Thus we had the confluence of biochemical data indicating unexpected modes of regulation for heterotrimeric G-proteins and data in model organisms implicating Gα and Gβγ in control of asymmetric cell division. One of the many interesting aspects of the signaling role played by G-proteins in the asymmetric cell division in the model organisms was that the process was apparently an intrinsically regulated event independent of a cell surface receptor. This initiated a lot of discussion in the literature about the implications of such a functional role for G-proteins, how this process is regulated and what G-proteins might be involved with in the cell independent of their well-characterized role as transducers from cell-surface GPCRs. The investigations alluded to above revealed four major concepts that have altered our basic concepts of G-protein signaling: 1) Gα and Gαβγ are processing signals within the cell distinct from their role as transducers for cell surface receptors; 2) such signals involve previously unrecognized functional roles for heterotrimeric G-protein subunits; 3) Gα and Gβγ may exist complexed with alternative binding partners independent of the classical Gαβγ heterotrimer; and 4) the G-protein activation/deactivation cycle may be regulated independent of nucleotide exchange. This review focuses on the group of proteins defined in a yeast-based functional screen as receptor-independent activators of G-protein signaling or AGS proteins. The goal of the review is to highlight concepts evolving from the discovery of alternative modes of G-protein regulation via AGS proteins, to discuss various unresolved issues in the field and to provide information on the current status of our knowledge regarding functional roles of AGS proteins. The reader is referred to other reviews for a broader discussion of additional G-protein regulators and a more detailed discussion of the discovery of AGS proteins and their initial characterization along with a more extensive listing of citations (Blumer et al., 2005; Cismowski and Lanier, 2005; Sato et al., 2006a). 2. STRATEGY TO IDENTIFY RECEPTOR-INDEPENDENT ACTIVATORS OF G-PROTEINS A series of experimental approaches were developed in our laboratory and others to identify novel proteins that directly regulate the activation state of G-proteins. One approach involved the influence of cell and tissue extracts on nucleotide binding to purified G-proteins and a second approach utilized a yeast-based functional screen (Cismowski et al., 2002; Cismowski et al., 1999; Ribas et al., 2002a; Takesono et al., 1999). The first approach resulted in the partial purification and characterization of the NG108-15 G-protein activator (Sato et al., 1996). This protein activates both heterotrimeric brain G-protein and free Gα and exhibits mechanistic properties that are distinct from receptor-mediated activation of G-protein (Ribas et al., 2002b). The second approach involved an expression cloning system utilizing the pheromone response pathway in S. cerevisiae (Cao et al., 2004; Cismowski et al., 2002; Cismowski et al., 1999; Sato et al., 2006b; Takesono et al., 1999). The pheromone response pathway in S. cerevisiae involves the pheromone receptor as a typical GPCR and a heterotrimeric G-protein with Gβγ coupling to a kinase cascade that regulates mating behavior and growth. Building upon the knowledge base for this system and the diversity of experimental tools developed in this genetically tractable organism, a yeast strain lacking the pheromone receptor and containing a modified mammalian Giα3 subunit was used to rapidly screen mammalian cDNAs for their ability to activate the pheromone response pathway in the absence of a receptor using a readout of inducible growth (Cismowski et al., 2002; Cismowski et al., 1999; Takesono et al., 1999). Gβγ subunit is the primary transducer in this signaling pathway activating the kinase cascade that forms the core of the pheromone response. This system is referred to in this review as the yeast-based functional assay and it was used to screen a panel of mammalian cDNA libraries (human heart, liver, brain and prostrate leiomyosarcoma, rat brain and transient ischemic myocardium, NG108-15 neuroblastoma) for entities that promoted the readout of growth. Secondary epistasis analysis allowed the identification of a group of cDNAs that required Gβγ for their bioactivity and this group of cDNAs were termed Activators of G-protein Signaling (AGS) (Table 1). In some cases, the AGS cDNA encodes a previously identified protein or gene product as indicated in Table 1.
2.1 PROTEINS IDENTIFIED AS RECEPTOR-INDEPENDENT ACTIVATORS OF G-PROTEIN SIGNALING The different cDNA libraries screened to date yielded 17 distinct cDNAs that promoted growth in the yeast functional screen. Ten of the isolated cDNAs require Gβγ to promote growth in the yeast screen and are therefore classified as activators of G-protein signaling as defined above (Figure 1
Although the end readout of growth for the AGS proteins reflects augmented Gβγ signaling, this may be achieved by various mechanisms. AGS proteins may act in the yeast system to: 1) promote G-protein activation as a guanine nucleotide exchange factor; 2) interfere with subunit interactions during basal cycling of nucleotide exchange and hydrolysis; 3) promote subunit dissociation or rearrangement independent of nucleotide exchange; 4) influence trafficking of G-protein subunits; and/or 5) bind to G-protein subunits co-translationally so that heterotrimeric Gαβγ is not formed. While this strategy isolated cDNAs defined as receptor independent activators of G-protein signaling, the proteins could conceivably also function as scaffolding proteins for G-protein subunits, effectors for Gβγ, chaperones for G-protein subunits and/or alternative binding partners for G-protein subunits independent of classical heterotrimeric Gαβγ. The AGS proteins isolated in this functional screen are actually part of a larger class of accessory proteins for G-protein signaling systems that are the subject of investigation in many laboratories (Sato et al., 2006a). 2.2 PROPERTIES OF AGS PROTEINS IN YEAST-BASED FUNCTIONAL SCREEN AND G-PROTEIN SUBUNIT BINDING The AGS proteins exhibited distinct properties in terms of G-protein regulation as determined in the yeast-based functional screen and by biochemical approaches even though they were isolated in the same basic functional screen (Figure 2
The properties of the different AGS proteins were initially studied in the yeast functional screen using yeast strains with different mammalian Gα subunits in combination with other known G-protein regulators and also in biochemical assays with purified proteins. The mechanism of G-protein activation by AGS1 appears similar to that of a GPCR in that it was inactive in yeast strains expressing G204A Giα2 and antagonized by overexpression of RGS4 (vida infra) and RGS5 (Cismowski et al., 2002; Cismowski et al., 1999; Takesono et al., 1999). In vitro, AGS1 interacted with Giα but not Gβγ and it increased GTPγS binding to purified G-protein. Giα2 G204A behaves as a dominant negative Gα subunit by virtue of its predicted low affinity for GTP and it is incapable of supporting signal propagation by an activated receptor in the yeast functional assay. In contrast, AGS2-8 were functional in the G204A Giα2 genetic background and in the presence of overexpressed RGS4. Thus, AGS2-8 differed from AGS1 and apparently activated heterotrimeric G-protein signaling by a mechanism independent of nucleotide exchange (Bernard et al., 2001; Cao et al., 2004; Cismowski et al., 1999; Sato et al., 2006b; Takesono et al., 1999) (Figure 2 Other than the presence of the GPR motif in the Group II AGS proteins, there are no generally conserved structural features for these proteins even though they were all isolated in the same functional screen. This is reflected in the diversity of mechanisms for regulation of G-protein signaling and the distinct functional roles associated with different AGS proteins (Figure 3
3. GROUP 1 AGS PROTEINS AGS1 was first discovered as s a dexamethasone-inducible, ras-related cDNA in AtT20 cells and termed DexRas (Kemppainen and Behrend, 1998) and subsequently named RASD1 by the HUGO Gene Nomenclature Committee. AGS1 was also identified in yeast two hybrid screens (Fang et al., 2000; Tu and Wu, 1999) and as a regulated cDNA in various other “discovery” platforms (Table 2). Among the superfamily of small G-proteins, AGS1 is most closely related (~60%) to Rhes (Ras homolog enriched in striatum) /TEM (Tumor endothelial marker) 2/RASD2 and exhibits a lower but likely significant sequence similarity to Rap proteins. AGS1 contains the conserved Ras-like motifs with additional extensions at the amino and carboxyl termini (Figure 2
3.1 BIOCHEMICAL CHARACTERIZATION OF AGS1 AND SIGNAL PROCESSING While several studies focused on the role of AGS1 in signal transduction as described below, we have relatively little information on the biochemical properties of AGS1 in terms of guanine nucleotide binding and hydrolysis, regulatory binding partners, subcellular distribution and posttranslational modifications. Several amino acids in AGS1 within key domains for nucleotide binding/hydrolysis differ from their counterparts in Ras (Figure 4A
GST-AGS1 isolated from yeast or bacteria does not readily bind GTPγS (Cismowski et al., 2000) except at fairly high concentrations of nucleotide and perhaps in the presence of a GEF (Fang et al., 2000). Side-by-side comparison of GST-AGS1 and the small G-protein GST-Cdc42 purified following expression in yeast indicated that AGS1 bound less nucleotide and that GTP binding predominated compared to parallel experiments with Cdc42. AGS1 exhibited a GTPase rate similar to that observed for GST-Cdc42 and suggesting that it may prefer the GTP bound state and that the lower amount of bound nucleotide reflects the hydrolysis of GTP and/or a lower affinity for GDP relative to Cdc42 (Cismowski et al., 2000). The nucleotide binding and hydrolysis properties of AGS1 may be quite different in mammalian systems due to the potential presence of regulatory proteins. Indeed, AGS1 expressed in HEK293 or AtT20 cells is predominantly GDP-bound (Fang et al., 2000; Graham et al., 2001). The signaling mechanisms of AGS1 and its cellular role remain incompletely understood. While several studies report the involvement of AGS1 in signal transduction, there is not a clear consensus on its signaling mechanism. AGS1 is implicated in a variety of signaling pathways including cAMP, Erk1/2 and NMDA-mediated signaling and as a Ras family member it likely has signaling roles independent of heterotrimeric G-protein signaling. The influence of AGS1 on G-protein signaling is complex. Certainly the yeast-based functional screen and initial biochemical studies indicate Gα regulation by AGS1 (Cismowski et al., 2000; Cismowski et al., 1999). The activity of AGS1 in the yeast functional assay is dependent upon nucleotide exchange on Gα and it is selective for Giα2 and Giα3. AGS1, purified as a GST fusion protein following expression in S. cerevisiae, increased GTPγS binding to purified Giα1 and Giα2 as well as purified brain G-protein heterotrimer. Thus, in this regard it differs mechanistically from a GPCR that couples only to heterotrimeric G-protein as well as from the GEF Ric 8A, which only behaves as a GEF for free Gα, but it is similar to the partially purified NG108-15 G-protein activator (Ribas et al., 2002b; Tall et al., 2003). Several other non-receptor accessory proteins also promote nucleotide exchange on G-proteins (Sato et al., 2006a) providing an additional impetus to the concepts of receptor independent signaling mechanisms for G-proteins developed in this review. However, Hiskens recently reported that in yeast two-hybrid assays, AGS1 specifically interacted with Gβ1 but not Giα2 and that AGS1 expressed in HEK cells coimmunoprecipitated with Gβ (Hiskens et al., 2005). The explanation for these disparate results is not clear, but may reflect differences in the nucleotide bound states of Gα or AGS1 in the different systems. In mammalian cells, transfected AGS1 activated the ERK1/2 pathway and this was blocked by pertussis toxin pretreatment or cotransfection with Gαt, which binds released Gβγ (Cismowski et al., 2000), though it cannot be ruled out that Gαt also binds AGS1 preventing activation of Giαβγ. The magnitude of inhibition of Erk1/2 by transfected AGS1 may be system-dependent (Graham et al., 2002; Nguyen and Watts, 2006, vida infra). AGS1 also inhibits cAMP accumulation in response to forskolin or a constitutive active Gsα (Graham et al., 2004), which is also consistent with regulation of Giα by AGS1. A role in regulating G-protein signaling events is also indicated by the ability of transfected AGS1 to block sensitization of adenylyl cyclase mediated by receptors coupled to Giα (Nguyen and Watts, 2006). The influence of AGS1 on G-protein regulated effectors such as adenylyl cyclase is further complicated by t he ability of AGS1 to inhibit PKCδ (Nguyen and Watts, 2006) and thus the outcome of various studies regarding AGS1 regulation of the effector AC is likely dependent upon the type of AC expressed in the cell of study. For example, transfected AGS1 inhibited phorbol ester stimulation of AC2 but did not alter Gαs-mediated regulation of AC2 and this was attributed to an action of AGS1 on PKCδ (Nguyen and Watts, 2006). On the other hand, AGS1 transfection blocked GPCR-mediated regulation of GIRK channels and Erk1/2 (Graham et al., 2002; Takesono et al., 2002), but not the inhibition of cAMP elicited by activation of receptors coupled to Giα (Nguyen and Watts, 2005) . Based upon the interaction of AGS1 with Giα and the data from the yeast-based functional assay discussed above, AGS1 may uncouple receptor from G-protein. AGS1 and a GPCR may “compete” for the available pool of G-proteins or perhaps an AGS1-initiated signal alters receptor – G-protein coupling (Graham et al., 2002; Takesono et al., 2002). Interaction of AGS1 with Gβγ might also explain these data as Erk1/2 and GIRK channels are Gβγ effectors (Hiskens et al., 2005). The AGS1-related protein Rhes blocked GPCR-Gsα mediated regulation of effectors, but not that regulated by receptors coupled to Giα (Vargiu et al., 2004). Following up on their initial isolation of AGS1 as a binding partner of CAPON, Snyder’s laboratory has developed a very interesting story indicating that AGS1 is nitrosylated in response to nNOS activation by NMDA receptors via CAPON docking and that this nitrosylation, which occurs on cysteine 11 in AGS1, accelerates nucleotide exchange on AGS1 and subsequent coupling to downstream effectors regulating iron transport and neuronal toxicity (Cheah et al., 2006; Jaffrey et al., 2002). The activation of AGS1 by NMDA receptors may provide an interface to heterotrimeric G-protein signaling systems as the NMDA mediated activation of Erk1/2 was inhibited by pertussis toxin (Chandler et al., 2001), which ADP ribosylates Gi/Go α subunits and blocks the effect of AGS1 in COS cells (Cismowski et al., 2000; Graham et al., 2002). One exciting functional connection for the work of Snyder’s laboratory on NMDA-mediated activation of AGS1 is provided by the studies of AGS1-/- mice generated by Cheng et al indicating that these mice exhibit changes in the NMDA-mediated influence on circadian rhythm (Cheng et al., 2004). In addition to its ability to regulate heterotrimeric G-proteins, AGS1 likely has functions independent of G-proteins involving more typical effectors for Ras-related proteins. AGS1 expression in some but not all cell types causes growth inhibition and this was not blocked by pertussis toxin (Vaidyanathan et al., 2004). The core effector domain of Ras (28FVDEYDPTIEDSY40) is similar to the corresponding region in AGS1 and Rhes (Figure 4 Thus, much work remains to be done to define the signaling role of AGS1. Most studies to date on this topic involve the use of transfected overexpression systems, which may complicate data interpretation and studies involving RNAi mediated knockdown of AGS1 may shed light on some of the issues in the field. The availability of AGS1-/- mice will also be of importance as these studies go forward (Cheng et al., 2004). 3.2 REGULATION OF AGS1 As basic information regarding the biochemistry, tissue distribution and signaling mechanisms of AGS1 has accumulated, the question remains as to its biological role in health and disease. Observations of note in this regard are the dramatic, tissue-specific, upregulation of AGS1 by dexamethasone in cultured cells and the intact animal (Brogan et al., 2001; Kemppainen and Behrend, 1998; Kemppainen et al., 2003) vida infra), the growth suppression observed upon AGS1 overexpression in some but not all cell types, the down-regulation of AGS1 (RASD1) in breast ductal carcinoma in situ (Abba et al., 2004), and changes in AGS1 mRNA during the circadian cycle in specific brain areas (Table 2). Glucocorticoids have diverse effects in the body and certainly play important roles in development and cell differentiation and it is interesting to suggest that some of their effects may be due to induction of AGS1 expression (Graham et al., 2001). AGS1 is also up-regulated in rat renal isografts from brain dead donors, which is consistent with its earlier isolation as a blood-loss inducible cDNA from kidney.1 Cell dessication and hypertonicity also increase AGS1 expression (Huang and Tunnacliffe, 2004). AGS1 mRNA is widely distributed with enrichment in the brain and both AGS1 and Rhes/RASD2 mRNA are increased following acute amphetamine (Harrison and LaHoste, 2006).2 Overall these data suggest a role of AGS1 in the response to cellular or tissue stress. If AGS1 is constitutively active, then the “signal input” to AGS1 may simply travel through transcriptional regulation as AGS1 mRNA is clearly upregulated by glucocorticoids and various stress-related stimuli. Translational control mechanisms may also be operative. If AGS1 is not constitutively active, then how is it regulated? One postulate concerns the activation through nitrosylation discussed above. It is also likely that there are other proteins that influence the nucleotide binding and hydrolysis properties of AGS1, which would provide a path for signal input to AGS1. 4. GROUP II AGS PROTEINS Group II AGS proteins are defined by the presence of at least one G-protein regulatory (GPR) motif, a 20-25 amino acid cassette that serves as a docking site for Gi/oα-GDP and Gtα (Figures 2
GPR motifs interact with Giα1-3, Gαt and exhibit lower and varying affinities for Gαo (Blumer et al., 2005). Individual GPR motifs may differ in their selectivity for individual Gαi isoforms (McCudden et al., 2005; Mittal and Linder, 2004; Shu et al., 2006) and regions outside of the core GPR motif can influence G-protein isoform selectivity (Adhikari and Sprang, 2003; Kimple et al., 2002; Kimple et al., 2004). AGS3-6 and other GPR-containing proteins provide an unexpected mode of regulation for signals involving Gi and Go G-proteins that is distinct from that achieved with the super family of GPCRs (Blumer et al., 2005; Sato et al., 2006a). The interaction of GPR motifs with Gαi/o stabilizes the GDP-bound conformation of Gα and interferes with Gβγ for binding to Giα (Blumer et al., 2005). The ability of a protein with multiple GPR motifs to bind an equivalent number of multiple Gαi/o at any given moment presents an unusual scaffolding potential for organizing a signaling cassette (Adhikari and Sprang, 2003; Bernard et al., 2001; Tall and Gilman, 2005). It will be of great interest to define the structural aspects of a multiple GPR motif protein in which each motif is docked with a Gα subunit. Such a structure might reveal an interaction of Gα subunits within the complex that would perhaps provide insight for their organization in other contexts. Functional studies with GPR proteins indicate a wide range of functional roles including an involvement in cell division, neuronal outgrowth, the biology of craving, autophagy and GIRK channel regulation (Bowers et al., 2004; Du and Macara, 2004; Guan et al., 2005; Lechler and Fuchs, 2005; Pattingre et al., 2003; Ron and Jurd, 2005; Sanada and Tsai, 2005; Sans et al., 2005; Wiser et al., 2006; Yao et al., 2005). The GPR motif may also represent a target for therapeutic manipulation and structure activity relationships have been defined (Figure 5 4.1 GPR PROTEINS AND SIGNAL PROCESSING With the discovery of an entity that behaves as a GDI for Gα and apparently activates heterotrimeric G-protein signaling in yeast independent of nucleotide exchange, the field was presented with an unexpected mode of G-protein regulation. The GPR motif may either promote dissociation of Gαβγ subunits, interfere with Gβγ binding to Gα, or a preformed GPR-Giα complex may await an incoming signal from a guanine nucleotide exchange factor that would initiate a GiαGTP or GPR regulated signaling cascade. One hypothesis based upon available data is that the GPR motif interacts with heterotrimeric Gαβγ and actively accelerates subunit dissociation (Bernard et al., 2001; Ghosh et al., 2003). GPR peptides enhance the rate of dissociation of a preformed heterotrimer and the enhanced rate of G protein subunit dissociation by GPR peptides was comparable to that of a known activator of G proteins, AMF (Ghosh et al., 2003). These data indicate that GPR proteins are not simply acting by competing for Gβγ binding GiαGDP and preventing reassembly of dissociated G-protein subunits. Indeed, several Gβγ binding peptides that dock at the Gαβγ interface and compete for Gα binding do not accelerate subunit dissociation (Davis et al., 2005; Ghosh et al., 2003). The structure of the GPR RGS14 GoLoco peptide with Gαi1 suggests that the binding site for the peptide does not directly bind to the Gβγ contact sites on Giα and that the binding site for a GPR motif (switch II/α3 helix binding pocket) on Gα is accessible in the heterotrimer Gαβγ (Kimple et al., 2002) (Figure 6
Functional studies concerning the role of G-proteins and GPR proteins in asymmetric cell division in D. melangaster and the developing rodent nervous system are consistent with a GPR protein acting upstream of heterotrimeric G-protein and promoting subunit dissociation (Sanada and Tsai, 2005; Schaefer et al., 2001; Yu et al., 2005). At present, it is not clear if a similar model of GPR-mediated activation of signaling operates in asymmetric cell division observed in the C. elegans embryo (Afshar et al., 2004; Bellaiche and Gotta, 2005; Couwenbergs et al., 2004; Srinivasan et al., 2003). The influence of GPR proteins on G-protein regulated ion channels has also been investigated. In HEK293 cells and X. laevis oocytes expressing GIRK1/2, LGN and GPR peptides activated basal Gβγ dependent K+ currents and siRNA knockdown of LGN decreased basal GIRK currents in primary neuronal cultures (Wiser et al., 2006). The GPR containing protein Pcp2/L7 also modulated receptor regulation of Cav2.1 calcium channels expressed in X. laevis oocytes (Kinoshita-Kawada et al., 2004), but did not modify basal current. On the other hand, perfusion of a GPR peptide into AtT-20 cells did not activate basal native K+ currents leading the authors to conclude that the GPR peptide could not dissociate G protein heterotrimers in cells (Webb et al., 2005). The explanation for these differences is not clear, but may relate to the importance of accessibility of G-proteins and placement of the GPR protein in various cellular environments. Inducible expression of Pcp2/L7 in PC12 cells elicited cell differentiation and this was blocked by the β-adrenergic receptor kinase Gβγ binding domain consistent with the GPR protein Pcp2/L7 promoting subunit dissociation (Guan et al., 2005). However, the effect of Pcp2/L7 in PC12 cells was also blocked by pertussis toxin, which may indicate the involvement of a receptor-mediated event. It is not known if Gα-GDP complexed with a GPR protein is a substrate for pertussis toxin as is the case for the heterotrimeric Gαβγ. Another mechanism by which GPR proteins may integrate into G-protein signaling is by existing as a complex with GiαGDP totally independent of heterotrimer as initially suggested by Takesono et al (Takesono et al., 1999). Indeed, subpopulations of GPR proteins and Giα-GDP are co-immunoprecipitated from cell extracts (Bernard et al., 2001). Of course, this leads to several questions. Where does this complex exist within the cell and how is its formation regulated? Is there a GEF for a GPR-GiαGDP complex that functions in a manner similar to that of a GPCR for classical Gαβγ? If there is a GEF for such a complex then what are the down stream effectors for either the GPR protein or GiαGTP? Studies by Tall and Gilman implicate Ric-8A as one such factor (Tall and Gilman, 2005). Ric-8A was isolated in a C. elegans genetic screen for entities that conferred resistance to inhibitors of acetylcholinesterase (Miller et al., 2000) and in yeast two-hybrid screens with Gαo (Tall et al., 2003). Purified mammalian Ric-8A increased GTPγS binding to Gαi1 bound to AGS3-short, LGN-short, full length LGN and a complex of LGN-NuMA (Tall and Gilman, 2005) contrasting with an earlier report suggesting that C. elegans Ric-8A did not effectively act as a GEF for a reconstituted GαGDP-GPR1/2 complex (Afshar et al., 2004). These differences may be due to the observation by Tall and Gilman that the myristoylated Giα1 complexed with a GPR protein was a much better substrate for Ric-8A as compared to unmyristoylated Giα1 (Tall and Gilman, 2005). Ric-8A promotes nucleotide exchange on Gαq, Giα1 and Gαo, whereas the Ric-8B isoform may augment Gαolf signaling (Von Dannecker et al., 2005). Functional studies regarding GPR motifs and G-protein-mediated regulation of various events in combination with biochemical approaches are beginning to provide a better operational understanding of this regulatory process. Although several lines of investigation support the role of Group II AGS proteins and related GPR proteins as receptor-independent activators of G-proteins, the role of GPR proteins in the processing of signals from GPCRs is not resolved. Overexpression of GPR proteins in various formats does not alter the ability of a Giα-coupled GPCR to inhibit the elevation of cellular cAMP elicited by forskolin or Gαs-coupled GPCRs (Sato et al., 2004). Overexpression of AGS4 also did not alter the Gβγ-mediated regulation of phospholipase C β2 (Cao et al., 2004). On the other hand, LGN modulates receptor-mediated regulation of GIRK channels (Wiser et al., 2006) and GPR-mediated modulation of receptor signaling may be operative in the function of AGS3 in addiction and craving (Bowers et al., 2004; Yao et al., 2005). A key control factor may be the positioning of the interacting proteins in the right place at the right time within the cell and such regulation may not be operative in a straightforward heterologous overexpression system. On the other hand, there is stronger evidence for a role of these proteins in the “adaptation” capability of GPCR systems. The sensitization of Gαs regulation of adenylyl cyclase observed with prolonged activation of a Giα-coupled GPCR is blocked by overexpression of AGS3 (Sato et al., 2004). AGS3 also plays an important role in the adaptive neuronal events associated with the biology of craving or desire, with some components mimicked with a GPR motif peptide (Bowers et al., 2004; Yao et al., 2005). In addition to the GPR peptides, a variety of approaches have also identified other peptide motifs and chemical compounds that influence the nucleotide binding, nucleotide hydrolysis and subunit interactions for heterotrimeric G-proteins (Bonacci et al., 2006; Cismowski and Lanier, 2005; Gilchrist et al., 2002; Hessling et al., 2003; Ja et al., 2005). Using an mRNA display strategy, Ja and Roberts identified a peptide sequence that binds GiαGDP (Ja et al., 2005; Ja and Roberts, 2004). Although the GPR motif was used as a starting point for the mRNA display strategy, the structural and mechanistic properties properties of the isolated peptide appear distinct from the GPR peptide (Ja et al., 2005; Ja and Roberts, 2004; Willard and Siderovski, 2006). The GiαGDP binding peptide KB-752, identified in a phage display using Giα-GDP, alter nucleotide binding properties of purified Giα1 and attenuates adenylyl cyclase (Johnston et al., 2005a; Johnston et al., 2005b). The X-ray crystal structure of the KB-752 peptide bound to Giα1 indicates that the peptide also binds in a cleft between switch II and the α3 helix altering the conformation of residues in switch II (Johnston et al., 2005b), as is the situation for the GPR-GoLoco RGS14 peptide (Kimple et al., 2002). However, the GPR peptide acts as a GDI and KB-752 acts as GEF for Giα. A key difference between these peptides is that the GPR motif also contacts the helical domain and introduces an arginine into the GDP binding site directly stabilizing GDP binding while KB-752 has a much more limited spatial interaction restricted to the switch II/α3 cleft (Johnston et al., 2005b; Kimple et al., 2002). The accumulating information regarding discrete targets on the G-protein subunits provides a potential platform for developing therapeutics that directly influence G-protein signaling by modulating nucleotide binding or hydrolysis, subunit interactions or by interfering with regulatory input from receptor-independent activators of G-protein signaling. 4.3 REGULATION OF GROUP II AGS PROTEINS One fundamental unresolved question is how GPR motif-containing proteins regulate their interactions with Giα subunits. One working hypothesis is that binding partners influence the subcellular distribution and/or the conformation of Group II AGS proteins such that their interaction with Giα is constrained within a specified microenvironment. This is certainly operative in the role these proteins play in asymmetric cell division discussed in the next section. Several GPR containing proteins possess other protein interaction modules that could serve to bind regulatory proteins influencing trafficking of the GPR protein or the interaction of GPR motifs with Gα subunits. This is perhaps best illustrated for AGS3 and LGN, which contain a series of TPR motifs upstream of the GPR domain (Figures 2
A number of interactions observed for Pins in Drosophila are evolutionarily conserved for its mammalian counterparts AGS3 and LGN with interactions mediated by their TPR and/or linker domains (Tables 3 and 4). With respect to the above discussion of the LGN-NuMA interaction, a NuMA homolog in Drosophila, Mud, was recently identified and demonstrated to bind Pins and regulate mitotic spindle orientation in neuroblasts (Bowman et al., 2006; Izumi et al., 2006; Siller et al., 2006). Analogous to the Insc-Pins interaction in Drosophila neuroblasts, LGN and AGS3 bind mInsc, the long sought-after mammalian homolog of Drosophila Insc, which modulates the orientation of the mitotic spindle and thus the cell fate of retinal progenitors and basal epidermal cells (Izaki et al., 2006; Lechler and Fuchs, 2005; Zigman et al., 2005). Drosophila Pins also binds discs-large (Dlg), a member of the MAGUK family of proteins, to control mitotic spindle orientation in sensory organ precursor cells (Bellaiche et al., 2001). Analagously, LGN interacts with members of the mammalian PSD-95 family of MAGUK proteins, namely SAP102, PSD-95, and SAP97/hDlg (Sans et al., 2005). It is unknown whether the LGN-hDlg interaction influences mitotic spindle positioning in mammalian cells; however, LGN interaction with SAP102, in conjuction with Giα subunits, modulates trafficking of NMDA receptor subunits to the plasma membrane and increases the density and size of dendritic spines in hippocampal neurons (Sans et al., 2005). Additional LGN binding partners include Lethal giant larvae 2 (Lgl2), which appears to connect LGN to the aPKC-Par6 complex in dividing HEK293 cells (Yasumi et al., 2005), Ha-Ras (Marty et al., 2003). In yet another evolutionarily conserved interaction, both AGS3 and Pins bind to the serine-threonine kinase LKB1 (DmLKB1 in Drosophila) which regulates oocyte polarity in Drosophila and is a tumor suppressor in mammals (Blumer et al., 2003; Martin and St Johnston, 2003). LKB1 was also recently identified as the upstream kinase for AMPK, a key regulator of energy homeostasis (Hawley et al., 2003; Woods et al., 2003). The role of AGS3 in these apparently diverse functions of LKB1 remains to be determined. LKB1 phosphorylates the GPR domains of both AGS3 and LGN, and phosphorylation of a conserved serine residue within the GPR motif blocks its interaction with Giα, thus implicating phosphorylation as a regulatory mechanism to modulate GPR - G-protein interaction (Blumer et al., 2003; Hollinger et al., 2003). In addition to the regulatory role of binding partners, the expression of both AGS3 and LGN is developmentally regulated. The levels of LGN appear to change with the cell cycle (Du and Macara, 2004; Whitfield et al., 2002). The relative expression of AGS3 mRNA encoding the full length protein or the shorter version lacking the TPR motifs in heart changes during the course of development (Pizzinat et al., 2001). Whereas, the expression of LGN in different brain areas of the rat is fairly stable with aging, the levels of AGS3 decline (Blumer et al., 2002; Sans et al., 2005). AGS3 is upregulated in the brain in a rat model of craving following cocaine exposure and this upregulation is important for adaptive neuronal processes (Bowers et al., 2004). 4.4 ROLE OF GPR PROTEINS IN CELL DIVISION While diverse functional roles for GPR proteins are observed as noted above and discussed in detail elsewhere, we will discuss only one of these which has matured quite rapidly over the last several years. Asymmetric cell division resulting in daughter cells of different cell fates, is one mechanism for achieving cell type diversity during development and was the area of investigation in which functional roles for GPR proteins proteins and the unexpected roles of G-proteins were first appreciated (Bellaiche et al., 2001; Gotta and Ahringer, 2001; Parmentier et al., 2000; Schaefer et al., 2001; Schaefer et al., 2000; Yu et al., 2000). The asymmetry of the division is derived not only from the different sizes of the daughter cells, but also, and perhaps more importantly, it involves the asymmetric localization of cell fate determinants which are specifically inherited by each daughter cell. Asymmetric cell division has been extensively studied in the model organisms Drosophila melanogaster and C. elegans (for review, see (Bellaiche and Gotta, 2005; Betschinger and Knoblich, 2004; Wang and Chia, 2005). In either case, asymmetric cell division employs the use of protein interaction cassettes to coordinate the transfer of polarity information to the dividing cell to specify the plane of division and simultaneously target cell fate determinants to the correct location for each daughter cell. In Drosophila neuroblasts, protein complexes containing Bazooka/Par-3, atypical PKC, and Par-6 are tethered to Pins-Giα complexes at the apical cortex by Insc. This complex is conserved in mammalian asymmetric divisions of the developing epidermis (Lechler and Fuchs, 2005) and atypical PKC-Par6-LGN complexes were also observed in mitotic HEK293 cell lysates (Yasumi et al., 2005). Correct targeting of this complex to the apical cortex of Drosophila neuroblasts is essential for asymmetric cell division to occur, and many of the proteins within this complex contribute to its overall stability. In C. elegans one-cell zygotes, interaction of the GPR motif-containing proteins GPR1/2 with Gα at the posterior cortex is critical for the proper asymmetric positioning of the mitotic spindle and this GPR motif-G protein interaction regulates differential cortical pulling forces on the spindle (Afshar et al., 2004; Colombo et al., 2003; Couwenbergs et al., 2004; Gotta et al., 2003; Srinivasan et al., 2003). In contrast to AGS3, AGS5/LGN and Pins, which have up to three (Pins) or four (AGS5/LGN, AGS3) GPR motifs, GPR1/2 has only one GPR motif. There is no obvious protein in higher organisms with a structural organization similar to GPR1/2. The molecular mechanism by which the spindle pulling forces might be regulated by GPR proteins and Gi/oα subunits is not yet defined, although recent data indicate a role for both an RGS protein and a non-receptor guanine nucleotide exchange factor, Ric-8 (Afshar et al., 2004; Couwenbergs et al., 2004; Hess et al., 2004). In D. melanogaster, the interactions between Pins, G-proteins and Ric-8 also play a key role in asymmetric division of neuroblasts and sensory organ precursor cells (Betschinger and Knoblich, 2004; David et al., 2005; Hampoelz et al., 2005; Wang et al., 2005). The role of the mammalian GPR proteins LGN and AGS3, which are 66% homologous, or G-proteins in cell division and polarity in higher organisms is an area of intense investigation. Recent reports indicate roles for these proteins in asymmetric cell division of neuronal precursors, retinal progenitors and cells of the developing epidermis (Lechler and Fuchs, 2005; Sanada and Tsai, 2005; Zigman et al., 2005) and cell division in the absence of polarity cues (Du and Macara, 2004; Kaushik et al., 2003). Certainly, LGN and Giα localize to subcellular structures (i.e. centrosomes, spindle pole, midbody, kinetochores) involved in control of cell division (Figure 8
The interaction of LGN with NuMA mentioned in the preceding section is an important component of the mechanism by which GPR proteins can regulate cell division. LGN binding to NuMA influences NuMA localization to the cortex where it is speculated to influence mitotic spindle positioning by modulating pulling forces on astral microtubules at the cortex via its interaction with the dynein/dynactin complex (Du and Macara, 2004). It should be noted that the LGN binding site on NuMA overlaps with its tubulin binding site and blocks NuMA binding to microtubules (Du et al., 2002). Tall and Gilman demonstrated that Giα bound to LGN-NuMA complexes serve as a substrate for the guanine nucleotide exchange factor Ric-8, and that after nucleotide exchange on Giβα has occurred, NuMA is released from LGN (Tall and Gilman, 2005). One obvious conclusion from these data is that Giα is not merely a membrane “tether” for LGN-NuMA complexes as has been suggested (Du and Macara, 2004), but may act as a switch, allowing a “ratcheting” of NuMA-mediated pulling forces on astral microtubules at the cortex by rapid cycling of nucleotide exchange on Giα and temporary release of NuMA from LGN as previously proposed (Tall and Gilman, 2005). An RGS protein may be a component of such a cycle for mammalian cells as determined for RGS7 in the integrated control of spindle pulling forces via G-proteins and Ric-8 in C. elegans (Hess et al., 2004). RGS14, which contains both an RGS and a GPR domain, is an attractive possibility for this role, as it is localized to spindle poles and the cell cortex during mitosis and also binds microtubules (Cho et al., 2005; Martin-McCaffrey et al., 2004; Martin-McCaffrey et al., 2005; Shu et al., 2006). One major outstanding question in the field is exactly how force is exerted on the spindle in order to reorient it relative to the complex of specified polarity determinants described above and the mechanisms by which G-proteins, the GPR-containing proteins AGS3 and AGS5/LGN and other accessory proteins for G-proteins interplay to influence these events. 5. GROUP III AGS PROTEINS As discussed earlier in the yeast-based functional assay, Group II and Group III AGS proteins are both active in the G204AGiα2 background and are not antagonized by overexpression of RGS5, which accelerates signal termination. However, Group II proteins bind Gα, whereas the Group III proteins AGS2 and AGS8 bind Gβγ. AGS10 or Goα also obviously binds Gβγ. However, the mechanisms by which the Group III AGS proteins activate G-protein signaling in the yeast functional screen and function in mammalian signaling systems are not yet fully understood. As more information becomes available, it is likely that members of this loosely defined Group III will exhibit different mechanisms of action in terms of their ability to lead to the end readout of Gβγ-dependent growth in the yeast functional screen. One mechanism by which the Group III proteins may act is by an interaction with Gβγ and the remainder of this section focuses on this concept. A central idea for both Group II and III AGS proteins is that they alter α-βγ subunit interactions releasing free βγ subunits that activate the yeast MAP kinase signaling system in the yeast functional assay. As discussed above, GPR containing AGS proteins may activate βγ signaling in yeast by altering the conformation of the Gα-switch II and either promoting subunit dissociation/rearrangement or compromising Gβγ subunit binding leading to accumulation of free Gβγ (Ghosh et al., 2003; Kimple et al., 2002; Peterson et al., 2000). In this scenario the free Gβγ subunits are not hindered with respect to target binding. A similar mechanism for Group III proteins that bind directly to Gβγ is more difficult to understand. Binding of Group III AGS proteins to the Gα subunit switch II-binding region on Gβγ, to compete for α subunit interactions, would simultaneously occlude an important effector binding interface on Gβγ. Thus we are presented with two possible considerations. First, the AGS protein in this group binds to a site on Gβγ other than the Gα subunit switch II-binding region on Gβγ and exerts allosteric influences on subunit interactions to “release” Gβγ for downstream signaling. Second, the AGS protein binds to the Gα subunit switch II-binding region on Gβγ and conformationally reveal a secondary effector regulation site. In either scenario, the AGS proteins would dissociate from Gβγ or remain bound to Gβγ when it interacts with an effector. This is further discussed below from the perspective of what is known about effector interactions with Gβγ subunits. 5.1 EFFECTOR RECOGNITION BY G PROTEIN βγ SUBUNITS - “HOTSPOTS” AND BEYOND Two major ideas concerning effector recognition by Gβγ subunits have emerged in the past 10 years. One is that a key interaction surface on Gβγ normally occluded by Gα subunits, mediates interactions with multiple effectors (Ford et al., 1998; Li et al., 1998). This region has been characterized as a “hot spot” that accommodates binding to structurally diverse effectors (Scott et al., 2001). “Hot Spots” are surfaces on proteins that by virtue of steric adaptability and the ability to form multiple types of chemical interactions are particularly well suited for mediating the energetics of diverse protein-protein interactions (Clackson and Wells, 1995; DeLano, 2002). During G-protein subunit dissociation or rearrangement this surface is thought to become exposed and allow binding and regulation of effectors (Hamm, 1998). A second view based on mutagenic and structural evidence from a variety of laboratories is that other surfaces of Gβγ subunits outside the “hot spot” are involved in interactions with different effectors and target proteins. For example, site directed mutagenesis of amino acids on the surface and sides of the Gβ subunit propeller structure that are not involved in interaction with Gα subunits, are required for activation of PLC β2, but not adenylyl cyclase (Panchenko et al., 1998). Chemical crosslinking and mutagenesis studies indicate an interaction of PLC β2 with the amino terminus of Gβ subunits, which does not overlap with the Gα subunit binding site (Yoshikawa et al., 2001). Yeast Gβ and Gγ subunits also possess putative effector binding sites that do not map to the “hot spot” (Leberer et al., 1992). Direct structural evidence for effector contacts with Gβγ outside of the “hot spot” in Gα is limited since only two of the many Gβγ subunit binding proteins, other than α subunits, have been co-crystallized with βγ subunits. One is phosducin, a Gβγ binding protein in the visual signal transduction system (Gaudet et al., 1996). Comparison of the phosducin structure with the heterotrimer structure reveals that the phosducin binding site on Gβγ overlaps extensively, but not completely, with the binding site for Gα. On the other hand, in the recently solved structure of Gβγ subunits in a complex with G protein coupled receptor kinase 2 (GRK2), the main amino acid contacts of Gβγ with the pleckstrin homology domain of GRK2 were similar to those contacting Gα (Lodowski et al., 2003). Overall, data suggest that effectors bind to βγ subunits at common core interaction site, but that alternate sites exist on βγ that could be important for binding and/or activation of effectors and could be exploited by Group III AGS proteins to propagate G protein signaling. 5.2 ACTIVATION OF G PROTEIN βγ SUBUNIT SIGNALING BY G PROTEIN βγ BINDING PEPTIDES Some insight into the possible mechanisms of action for those members of the Group III AGS proteins interacting with Gβγ could be perhaps gleaned by considering how a novel class of Gβγ binding peptides activates G protein signaling. Peptides that bind to the G protein “hot spot” were recently identified in a random peptide phage display screen (Scott et al., 2001). One of these peptides SIRK, has unique properties in that it binds directly at the α-subunit switch II binding site on Gβγ and actively promotes subunit dissociation (Davis et al., 2005; Scott et al., 2001). In addition, SIRK blocked activation of PLCβ and PI3K in vitro by Gβγ, yet stimulated Gβγ -regulated ERK activation in intact cells. One interpretation of these data is that the peptide occupied the “hot spot” on Gβγ blocking PLCβ and PI3K interactions, but effector sites on Gβγ outside the “hot spot” were used for ERK activation. Virtual docking of chemical compounds based upon the structure of the peptide-Gβγ structure led to the generation of small molecules selectively altering Gβγ signaling pathways in cells (Bonacci et al., 2006). This suggests that if Group III AGS proteins indeed occupied the “hot spot” on Gβγ, there may be an additional mechanism for regulation of effectors that bind to regions outside of the “hot spot”. Initial data available for the action of AGS8 provides a further platform for development of this concept. AGS8 was discovered as a receptor-independent activator of G-protein signaling upregulated during transient cardiac ischemia (Sato et al., 2006b). Initial characterization of AGS8 indicated that it bound to Gβγ subunits. Of particular interest, in transfected mammalian cells, AGS8 produced a small activation of PLCβ2, but completely reversed the inhibitory effect of Gα on Gβγ-mediated activation of PLCβ2. One interpretation of these data is that AGS8 prevents binding of Gα to the “hot spot” for effector interaction on Gβγ but yet does not impede Gβγ-mediated stimulation of PLCβ2, perhaps through an effector binding site distinct from the “hot spot”. 6. AGS AND RELATED PROTEINS IN SIGNAL ADAPTATION AND DISEASE The regulatory mechanisms operational with AGS proteins reveal unexpected diversity in the “G-switch” signaling mechanism and cellular functions regulated by G-proteins. This flurry of activity over the last 5-6 years has opened up new avenues for therapeutic manipulation of G-protein signaling and the expanded role that G-proteins may play in disease or tissue adaptation. Many questions remain to be addressed including the following. What controls the activity of AGS proteins? Are Gα and Gβγ playing a role within the cell independent of heterotrimer formation by complexing with alternative binding partners? If so, what provides signal input to such a complex and what is “downstream” of Gα and Gβγ functioning in this context? Are AGS proteins functioning as a component of an unexpected intracellular signaling network (Slessareva et al., 2006; Sorkin and Von Zastrow, 2002)? Do AGS and related proteins play a role in GPCR signaling as modulators or as organizational structures within a larger signal transduction complex? The regulatory mechanisms operational for AGS proteins also may relate to other evolving concepts regarding G-protein signaling systems and the dynamics of G-protein activation and deactivation. Recent FRET based analyses suggest that G-protein heterotrimers may not physically dissociate upon activation by certain receptors (Bunemann et al., 2003; Frank et al., 2005), but rather undergo a ill-defined rearrangement of subunits to allow binding of effectors and other regulators. Indeed, a covalently linked α-βγ fusion protein is signaling competent in yeast consistent with the idea that physical subunit dissociation is not necessarily required for G protein signaling (Klein et al., 2000). This concept is also supported by the kinetic coupling model for the action of RGS proteins indicating that in the presence of RGS proteins, GTP hydrolysis is too rapid to allow dissociation of Gα and Gβγ prior to effector activation (Ross and Wilkie, 2000). An interesting thought was presented by Ugur and Onaran with their observation that the β2-adrenergic receptor could activate adenylyl cyclase without causing nucleotide exchange on Gsα (Ugur et al., 2005). From the perspective of disease and therapeutics, several thoughts emerge. AGS1 may be of particular interest in terms of cell growth and differentiation and an expanded analysis of AGS1 mutants that may be associated with disease states would be of value. The GPR motif present in Group II AGS proteins has presented itself as a therapeutic target (Bowers et al., 2004) in modulating desire and given the role of GPR proteins in cell division, a similar strategy may be of value in manipulating stem cell propagation or uncontrolled cell growth. Recent success with small molecules targeting Gβγ (Bonacci et al., 2006), suggests that the mechanisms of Gβγ regulation by the Group III AGS proteins may provide an additional platform for expansion of this strategy. Finally, it is likely that additional receptor-independent activators of G-protein signaling will surface as the yeast-based functional screen is expanded. AGS proteins that are upregulated in disease states or as part of a tissue adaptation program can likely be identified by screening a panel of cDNA libraries generated from human disease tissue in the yeast-based discovery platform. Proof of concept with this approach is provided by Sato et al (Sato et al., 2006b) and the functional screen of cDNA libraries from rat ischemic myocardium and a prostate leiomyosarcoma (Cao et al., 2004; Sato et al., 2006b). Acknowledgments This work was supported by MH90531 (SML), NS24821 (SML), GM074247 (SML), F32MH65092 (JBB), GM053536 (AVS) and GM060286 (AVS) from the National Institutes of Health. SML is greatly appreciative for this support and that provided by the David R. Bethune/Lederle Laboratories Professorship in Pharmacology and the Research Scholar Award from Yamanouchi Pharmaceutical Company, LTD (Astellas Pharma). SML also appreciates the sustained collaboration with Drs. Emir Duzic, Mary Cismowski and John Hildebrandt during the course of our investigations. The authors acknowledge the continuous input provided to this effort over the years by the many fellows and students that have spent time in the laboratory and the many colleagues with which we have had the pleasure of working with.. Abbreviations Footnotes 1Mammalian Blood Loss-Induced Gene, KD312, Amgen US patent 6,462,177 2Schwendt, M., Chandler, L.J., Blumer, J.B., Lanier, S.M., and McGinty, J.F. Expression of Activator of G-protein Signaling AGS1/DexRas1 in the Rat Brain Increases During Development and in Response to Acute Amphetamine. (2005) Abstract, Society of Neuroscience, San Diego, CA. 3The GPR motif is also known as the GoLoco motif (Siderovski et al., 1999). Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errorsmaybe discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. LITERATURE CITED
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||
Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]Annu Rev Pharmacol Toxicol. 2006; 46():151-87.
[Annu Rev Pharmacol Toxicol. 2006]J Cell Biol. 1991 Sep; 114(6):1113-24.
[J Cell Biol. 1991]Endocrinology. 1994 Jan; 134(1):233-44.
[Endocrinology. 1994]Nat Cell Biol. 2001 Mar; 3(3):297-300.
[Nat Cell Biol. 2001]Nature. 2003 Jan 16; 421(6920):231-7.
[Nature. 2003]Curr Biol. 2004 Aug 24; 14(16):R674-85.
[Curr Biol. 2004]Cell. 2001 Aug 10; 106(3):355-66.
[Cell. 2001]J Neurosci. 2000 Jul 15; 20(14):RC84.
[J Neurosci. 2000]Trends Pharmacol Sci. 2005 Sep; 26(9):470-6.
[Trends Pharmacol Sci. 2005]Annu Rev Pharmacol Toxicol. 2006; 46():151-87.
[Annu Rev Pharmacol Toxicol. 2006]Methods Enzymol. 2002; 344():153-68.
[Methods Enzymol. 2002]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]J Biol Chem. 1996 Nov 22; 271(47):30052-60.
[J Biol Chem. 1996]J Biol Chem. 2002 Dec 27; 277(52):50223-5.
[J Biol Chem. 2002]Methods Enzymol. 2002; 344():153-68.
[Methods Enzymol. 2002]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]Annu Rev Pharmacol Toxicol. 2006; 46():151-87.
[Annu Rev Pharmacol Toxicol. 2006]Methods Enzymol. 2002; 344():153-68.
[Methods Enzymol. 2002]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]J Biol Chem. 2001 Jan 12; 276(2):1585-93.
[J Biol Chem. 2001]J Biol Chem. 2004 Jun 25; 279(26):27567-74.
[J Biol Chem. 2004]J Biol Chem. 1998 Feb 6; 273(6):3129-31.
[J Biol Chem. 1998]Neuron. 2000 Oct; 28(1):183-93.
[Neuron. 2000]Biochim Biophys Acta. 1999 Dec 23; 1489(2-3):452-6.
[Biochim Biophys Acta. 1999]Biochemistry. 1991 May 14; 30(19):4637-48.
[Biochemistry. 1991]Mol Cell Biol. 1996 Jun; 16(6):2689-99.
[Mol Cell Biol. 1996]J Cell Biol. 1998 Apr 6; 141(1):187-97.
[J Cell Biol. 1998]Endocrinology. 2001 Jun; 142(6):2631-40.
[Endocrinology. 2001]J Biol Chem. 2000 Aug 4; 275(31):23421-4.
[J Biol Chem. 2000]Neuron. 2000 Oct; 28(1):183-93.
[Neuron. 2000]Endocrinology. 2001 Jun; 142(6):2631-40.
[Endocrinology. 2001]J Biol Chem. 2000 Aug 4; 275(31):23421-4.
[J Biol Chem. 2000]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 2002 Dec 27; 277(52):50223-5.
[J Biol Chem. 2002]J Biol Chem. 2003 Mar 7; 278(10):8356-62.
[J Biol Chem. 2003]Annu Rev Pharmacol Toxicol. 2006; 46():151-87.
[Annu Rev Pharmacol Toxicol. 2006]J Biol Chem. 2000 Aug 4; 275(31):23421-4.
[J Biol Chem. 2000]J Biol Chem. 2002 Mar 29; 277(13):10876-82.
[J Biol Chem. 2002]Mol Pharmacol. 2006 May; 69(5):1763-71.
[Mol Pharmacol. 2006]Biochem Biophys Res Commun. 2004 Apr 2; 316(2):307-12.
[Biochem Biophys Res Commun. 2004]J Biol Chem. 2002 Mar 29; 277(13):10876-82.
[J Biol Chem. 2002]J Biol Chem. 2002 Apr 19; 277(16):13827-30.
[J Biol Chem. 2002]Biochem Biophys Res Commun. 2005 Jul 8; 332(3):913-20.
[Biochem Biophys Res Commun. 2005]Biochem Biophys Res Commun. 2005 Dec 2; 337(4):1038-46.
[Biochem Biophys Res Commun. 2005]Oncogene. 2004 Jan 15; 23(2):559-68.
[Oncogene. 2004]Neuron. 2006 Aug 17; 51(4):431-40.
[Neuron. 2006]Chem Biol. 2002 Dec; 9(12):1329-35.
[Chem Biol. 2002]J Biol Chem. 2001 Jan 26; 276(4):2627-36.
[J Biol Chem. 2001]J Biol Chem. 2000 Aug 4; 275(31):23421-4.
[J Biol Chem. 2000]J Biol Chem. 2002 Mar 29; 277(13):10876-82.
[J Biol Chem. 2002]Oncogene. 2004 Jul 29; 23(34):5858-63.
[Oncogene. 2004]Oncogene. 2004 Jan 15; 23(2):559-68.
[Oncogene. 2004]Neuron. 2004 Sep 2; 43(5):715-28.
[Neuron. 2004]Neuroendocrinology. 2001 Oct; 74(4):244-50.
[Neuroendocrinology. 2001]J Biol Chem. 1998 Feb 6; 273(6):3129-31.
[J Biol Chem. 1998]Biochim Biophys Acta. 2003 Jun 19; 1627(2-3):85-9.
[Biochim Biophys Acta. 2003]Breast Cancer Res. 2004; 6(5):R499-513.
[Breast Cancer Res. 2004]Endocrinology. 2001 Jun; 142(6):2631-40.
[Endocrinology. 2001]J Biol Chem. 2001 Jan 12; 276(2):1585-93.
[J Biol Chem. 2001]Trends Pharmacol Sci. 2005 Sep; 26(9):470-6.
[Trends Pharmacol Sci. 2005]J Biol Chem. 2000 Oct 27; 275(43):33193-6.
[J Biol Chem. 2000]Annu Rev Pharmacol Toxicol. 2006; 46():151-87.
[Annu Rev Pharmacol Toxicol. 2006]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]Trends Pharmacol Sci. 2005 Sep; 26(9):470-6.
[Trends Pharmacol Sci. 2005]J Biol Chem. 2004 Nov 5; 279(45):46772-8.
[J Biol Chem. 2004]J Biol Chem. 2003 Dec 19; 278(51):51825-32.
[J Biol Chem. 2003]Nature. 2002 Apr 25; 416(6883):878-81.
[Nature. 2002]Biochem J. 2004 Mar 15; 378(Pt 3):801-8.
[Biochem J. 2004]Neuron. 2004 Apr 22; 42(2):269-81.
[Neuron. 2004]Cell. 2004 Nov 12; 119(4):503-16.
[Cell. 2004]Biochem J. 2005 Dec 1; 392(Pt 2):389-97.
[Biochem J. 2005]Nature. 2005 Sep 8; 437(7056):275-80.
[Nature. 2005]J Biol Chem. 2003 Jun 6; 278(23):20995-1002.
[J Biol Chem. 2003]J Biol Chem. 2001 Jan 12; 276(2):1585-93.
[J Biol Chem. 2001]J Biol Chem. 2003 Sep 12; 278(37):34747-50.
[J Biol Chem. 2003]Biochemistry. 2005 Aug 9; 44(31):10593-604.
[Biochemistry. 2005]Nature. 2002 Apr 25; 416(6883):878-81.
[Nature. 2002]Nature. 1994 Jun 23; 369(6482):621-8.
[Nature. 1994]Cell. 1995 Dec 15; 83(6):1047-58.
[Cell. 1995]Cell. 2005 Jul 15; 122(1):119-31.
[Cell. 2005]Cell. 2001 Oct 19; 107(2):183-94.
[Cell. 2001]Genes Dev. 2005 Jun 1; 19(11):1341-53.
[Genes Dev. 2005]Cell. 2004 Oct 15; 119(2):219-30.
[Cell. 2004]Curr Opin Cell Biol. 2005 Dec; 17(6):658-63.
[Curr Opin Cell Biol. 2005]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]J Biol Chem. 2001 Jan 12; 276(2):1585-93.
[J Biol Chem. 2001]Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16584-9.
[Proc Natl Acad Sci U S A. 2005]Neuron. 2000 Aug; 27(2):289-99.
[Neuron. 2000]J Biol Chem. 2003 Mar 7; 278(10):8356-62.
[J Biol Chem. 2003]J Biol Chem. 2004 Apr 2; 279(14):13375-82.
[J Biol Chem. 2004]J Biol Chem. 2004 Jun 25; 279(26):27567-74.
[J Biol Chem. 2004]Neuron. 2006 May 18; 50(4):561-73.
[Neuron. 2006]Neuron. 2004 Apr 22; 42(2):269-81.
[Neuron. 2004]Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8746-51.
[Proc Natl Acad Sci U S A. 2005]Science. 2006 Apr 21; 312(5772):443-6.
[Science. 2006]Sci STKE. 2002 Feb 5; 2002(118):pl1.
[Sci STKE. 2002]Biochem Pharmacol. 2003 Mar 15; 65(6):961-7.
[Biochem Pharmacol. 2003]J Biol Chem. 2005 Sep 16; 280(37):32057-60.
[J Biol Chem. 2005]Biochemistry. 2004 Jul 20; 43(28):9265-75.
[Biochemistry. 2004]Nat Cell Biol. 2001 Dec; 3(12):1069-75.
[Nat Cell Biol. 2001]Cell. 2004 Nov 12; 119(4):503-16.
[Cell. 2004]Dev Cell. 2006 Jun; 10(6):731-42.
[Dev Cell. 2006]Nat Cell Biol. 2006 Jun; 8(6):586-93.
[Nat Cell Biol. 2006]Nat Cell Biol. 2006 Jun; 8(6):594-600.
[Nat Cell Biol. 2006]Biochem Biophys Res Commun. 2006 Mar 24; 341(4):1001-6.
[Biochem Biophys Res Commun. 2006]Nature. 2005 Sep 8; 437(7056):275-80.
[Nature. 2005]J Biol Chem. 2003 Jun 27; 278(26):23217-20.
[J Biol Chem. 2003]Nature. 2003 Jan 23; 421(6921):379-84.
[Nature. 2003]J Biol. 2003; 2(4):28.
[J Biol. 2003]Curr Biol. 2003 Nov 11; 13(22):2004-8.
[Curr Biol. 2003]Biochemistry. 2003 Jan 28; 42(3):811-9.
[Biochemistry. 2003]Cell. 2004 Nov 12; 119(4):503-16.
[Cell. 2004]Mol Biol Cell. 2002 Jun; 13(6):1977-2000.
[Mol Biol Cell. 2002]J Biol Chem. 2001 May 18; 276(20):16601-10.
[J Biol Chem. 2001]J Biol Chem. 2002 May 3; 277(18):15897-903.
[J Biol Chem. 2002]Neuron. 2004 Apr 22; 42(2):269-81.
[Neuron. 2004]Cell. 2001 Aug 10; 106(3):355-66.
[Cell. 2001]Nat Cell Biol. 2001 Mar; 3(3):297-300.
[Nat Cell Biol. 2001]J Neurosci. 2000 Jul 15; 20(14):RC84.
[J Neurosci. 2000]Cell. 2001 Oct 19; 107(2):183-94.
[Cell. 2001]Curr Biol. 2000 Apr 6; 10(7):353-62.
[Curr Biol. 2000]Curr Opin Cell Biol. 2005 Dec; 17(6):658-63.
[Curr Opin Cell Biol. 2005]Curr Biol. 2004 Aug 24; 14(16):R674-85.
[Curr Biol. 2004]Biol Cell. 2005 Jan; 97(1):63-74.
[Biol Cell. 2005]Nature. 2005 Sep 8; 437(7056):275-80.
[Nature. 2005]J Biol Chem. 2005 Feb 25; 280(8):6761-5.
[J Biol Chem. 2005]Cell. 2004 Oct 15; 119(2):219-30.
[Cell. 2004]Science. 2003 Jun 20; 300(5627):1957-61.
[Science. 2003]Curr Biol. 2004 Oct 26; 14(20):1871-6.
[Curr Biol. 2004]Curr Biol. 2003 Jun 17; 13(12):1029-37.
[Curr Biol. 2003]Genes Dev. 2003 May 15; 17(10):1225-39.
[Genes Dev. 2003]Nature. 2005 Sep 8; 437(7056):275-80.
[Nature. 2005]Cell. 2005 Jul 15; 122(1):119-31.
[Cell. 2005]Neuron. 2005 Nov 23; 48(4):539-45.
[Neuron. 2005]Cell. 2004 Nov 12; 119(4):503-16.
[Cell. 2004]Mol Biol Cell. 2003 Aug; 14(8):3144-55.
[Mol Biol Cell. 2003]Cell. 2004 Nov 12; 119(4):503-16.
[Cell. 2004]Curr Biol. 2002 Nov 19; 12(22):1928-33.
[Curr Biol. 2002]Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16584-9.
[Proc Natl Acad Sci U S A. 2005]Cell. 2004 Oct 15; 119(2):209-18.
[Cell. 2004]J Biol Chem. 2005 Jan 7; 280(1):805-14.
[J Biol Chem. 2005]J Biol Chem. 2003 Sep 12; 278(37):34747-50.
[J Biol Chem. 2003]Nature. 2002 Apr 25; 416(6883):878-81.
[Nature. 2002]J Biol Chem. 2000 Oct 27; 275(43):33193-6.
[J Biol Chem. 2000]Science. 1998 May 22; 280(5367):1271-4.
[Science. 1998]J Biol Chem. 1998 Jun 26; 273(26):16265-72.
[J Biol Chem. 1998]EMBO J. 2001 Feb 15; 20(4):767-76.
[EMBO J. 2001]Science. 1995 Jan 20; 267(5196):383-6.
[Science. 1995]Curr Opin Struct Biol. 2002 Feb; 12(1):14-20.
[Curr Opin Struct Biol. 2002]Cell. 1996 Nov 1; 87(3):577-88.
[Cell. 1996]Science. 2003 May 23; 300(5623):1256-62.
[Science. 2003]EMBO J. 2001 Feb 15; 20(4):767-76.
[EMBO J. 2001]Biochemistry. 2005 Aug 9; 44(31):10593-604.
[Biochemistry. 2005]Science. 2006 Apr 21; 312(5772):443-6.
[Science. 2006]Proc Natl Acad Sci U S A. 2006 Jan 17; 103(3):797-802.
[Proc Natl Acad Sci U S A. 2006]Cell. 2006 Jul 14; 126(1):191-203.
[Cell. 2006]Nat Rev Mol Cell Biol. 2002 Aug; 3(8):600-14.
[Nat Rev Mol Cell Biol. 2002]Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):16077-82.
[Proc Natl Acad Sci U S A. 2003]J Biol Chem. 2005 Jul 1; 280(26):24584-90.
[J Biol Chem. 2005]Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3219-23.
[Proc Natl Acad Sci U S A. 2000]Annu Rev Biochem. 2000; 69():795-827.
[Annu Rev Biochem. 2000]Mol Pharmacol. 2005 Sep; 68(3):720-8.
[Mol Pharmacol. 2005]Neuron. 2004 Apr 22; 42(2):269-81.
[Neuron. 2004]Science. 2006 Apr 21; 312(5772):443-6.
[Science. 2006]Proc Natl Acad Sci U S A. 2006 Jan 17; 103(3):797-802.
[Proc Natl Acad Sci U S A. 2006]J Biol Chem. 2004 Jun 25; 279(26):27567-74.
[J Biol Chem. 2004]Methods Enzymol. 2002; 344():153-68.
[Methods Enzymol. 2002]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]Oncogene. 2004 Jul 29; 23(34):5858-63.
[Oncogene. 2004]J Biol Chem. 2002 Mar 1; 277(9):6767-70.
[J Biol Chem. 2002]Cell. 1995 Dec 15; 83(6):1047-58.
[Cell. 1995]Nature. 2002 Apr 25; 416(6883):878-81.
[Nature. 2002]J Biol Chem. 2004 Jun 25; 279(26):27567-74.
[J Biol Chem. 2004]Nat Biotechnol. 1999 Sep; 17(9):878-83.
[Nat Biotechnol. 1999]J Biol Chem. 1999 Nov 19; 274(47):33202-5.
[J Biol Chem. 1999]Trends Biochem Sci. 1999 Sep; 24(9):340-1.
[Trends Biochem Sci. 1999]